



House of Representatives

General Assembly

File No. 81

February Session, 2012

Substitute House Bill No. 5244

House of Representatives, March 22, 2012

The Committee on Public Health reported through REP. RITTER, E. of the 38th Dist., Chairperson of the Committee on the part of the House, that the substitute bill ought to pass.

***AN ACT CONCERNING COLLABORATIVE FUNDING AGREEMENTS
AND THE STEM CELL RESEARCH PROGRAM.***

Be it enacted by the Senate and House of Representatives in General Assembly convened:

1 Section 1. Section 19a-32e of the general statutes is repealed and the
2 following is substituted in lieu thereof (*Effective October 1, 2012*):

3 (a) There is established the "Stem Cell Research Fund" which shall
4 be a separate, nonlapsing account within the General Fund. The fund
5 may contain any moneys required or permitted by law to be deposited
6 in the fund and any funds received from any public or private
7 contributions, gifts, grants, donations, bequests or devises to the fund.
8 The Commissioner of Public Health may (1) make grants-in-aid from
9 the fund in accordance with the provisions of subsection (b) of this
10 section, or (2) enter into agreements with other entities, including, but
11 not limited to, states or foreign countries, to advance research
12 collaboration opportunities for a recipient of a grant-in-aid.

13 (b) [Not later than June 30, 2006, the] The Stem Cell Research

14 Advisory Committee established pursuant to section 19a-32f shall
 15 develop an application for grants-in-aid under this section for the
 16 purpose of conducting embryonic or human adult stem cell research
 17 and may receive applications from eligible institutions for such grants-
 18 in-aid. [on and after said date.] The Stem Cell Research Advisory
 19 Committee shall require any applicant for a grant-in-aid under this
 20 section to conduct stem cell research to submit (1) a complete
 21 description of the applicant's organization, (2) the applicant's plans for
 22 stem cell research and proposed funding for such research from
 23 sources other than the state of Connecticut, and (3) proposed
 24 arrangements concerning financial benefits to the state of Connecticut
 25 as a result of any patent, royalty payment or similar rights developing
 26 from any stem cell research made possible by the awarding of such
 27 grant-in-aid. Said committee shall direct the Commissioner of Public
 28 Health with respect to the awarding of such grants-in-aid after
 29 considering recommendations from the Stem Cell Research Peer
 30 Review Committee established pursuant to section 19a-32g.

31 (c) Commencing with the fiscal year ending June 30, 2006, and for
 32 each of the nine consecutive fiscal years thereafter, until the fiscal year
 33 ending June 30, 2015, not less than ten million dollars shall be available
 34 from the Stem Cell Research Fund for grants-in-aid to eligible
 35 institutions for the purpose of conducting embryonic or human adult
 36 stem cell research, as directed by the Stem Cell Research Advisory
 37 Committee established pursuant to section 19a-32f and in accordance
 38 with the provisions of section 19a-32d. Any balance of such amount
 39 not used for such grants-in-aid during a fiscal year shall be carried
 40 forward for the fiscal year next succeeding for such grants-in-aid.

This act shall take effect as follows and shall amend the following sections:		
---	--	--

Section 1	October 1, 2012	19a-32e
-----------	-----------------	---------

Statement of Legislative Commissioners:

In section 1 (b), in the first sentence "grants-in-aid on and after said date" was changed to "grants-in-aid. [on and after said date.]" for

accuracy and consistency with the change made at the beginning of the sentence.

PH *Joint Favorable Subst.-LCO*

The following Fiscal Impact Statement and Bill Analysis are prepared for the benefit of the members of the General Assembly, solely for purposes of information, summarization and explanation and do not represent the intent of the General Assembly or either chamber thereof for any purpose. In general, fiscal impacts are based upon a variety of informational sources, including the analyst's professional knowledge. Whenever applicable, agency data is consulted as part of the analysis, however final products do not necessarily reflect an assessment from any specific department.

OFA Fiscal Note**State Impact:** None**Municipal Impact:** None**Explanation**

The bill does not result in a fiscal impact to the state or municipalities. It authorizes the Department of Public Health to enter into agreements with states, foreign countries, and other entities to advance research collaboration opportunities for stem cell research grant recipients. Funding disbursements from the Tobacco Settlement Fund (TSF) to the Stem Cell Research Fund (SCRF)¹ are not altered.

The Out Years**State Impact:** None**Municipal Impact:** None

Sources: Office of Fiscal Analysis, Tobacco Settlement Fund Memo, 11/18/11

¹ PA 05-149 authorized annual expenditures in FY 06 through FY 15 from a newly established SCRF for embryonic and human adult stem cell research. In the first two years of this ten year initiative (FY 06 and FY 07), \$20.0 million was appropriated from the General Fund to support the SCRF. In each of FY 08 through FY 15, \$10.0 million has been authorized to be disbursed to the SCRF from the TSF.

OLR Bill Analysis**sHB 5244*****AN ACT CONCERNING COLLABORATIVE FUNDING AGREEMENTS AND THE STEM CELL RESEARCH PROGRAM.*****SUMMARY:**

This bill authorizes the public health commissioner to enter into agreements with states, foreign countries, and other entities to advance collaborative research opportunities for Stem Cell Research Fund grant recipients. By law, the commissioner chairs the Stem Cell Research Advisory Committee, which directs the commissioner in making annual grants from the fund to eligible institutions for embryonic and human adult stem cell research.

The bill specifies that grant recipients must comply with statutory conditions for stem cell research in the state, including, among other things:

1. consent requirements for prospective embryo donors,
2. standards for the use of human embryonic stem cell lines derived outside Connecticut,
3. oversight of in-state human embryonic stem cell research by embryonic stem cell review oversight committees, and
4. compliance with the National Academies' "Guidelines for Human Embryonic Stem Cell Research."

EFFECTIVE DATE: October 1, 2012

BACKGROUND***National Academies***

The National Academies is an independent organization chartered

by Congress to advise the government on scientific, engineering, and health matters. In 2005, it released guidelines and recommendations for human embryonic stem cell research which are amended from time to time (most recently in 2010). These guidelines are intended for use by the scientific community, including researchers in academic, industry, or other private sector organizations.

COMMITTEE ACTION

Public Health Committee

Joint Favorable

Yea 25 Nay 0 (03/09/2012)